Login / Signup

Biological evaluation of hesperidin for direct pulp capping in dogs' teeth.

Ebtesam O Abo El-MalAshraf Mohamed Abu-SeidaSalma H El Ashry
Published in: International journal of experimental pathology (2021)
This study compared the biological effect of Hesperidin, Mineral Trioxide Aggregate (MTA)-Angelus and calcium hydroxide for direct pulp capping. A total of 126 dogs, teeth were divided according to the post-treatment evaluation period into three groups (42 teeth each), group I: 2 weeks, group II: 4 weeks and group III: 8 weeks. Each group was further subdivided according to the pulp capping material into three subgroups (14 teeth each), subgroup A (Hesperidin), subgroup B (MTA-Angelus) and subgroup C (Dycal). Both inflammatory response and dentine bridge formation were assessed by histopathology. All data were statistically analysed. Resolution of the inflammation was recorded by the time with a significant difference between subgroups   within the same group (P<.05). Hesperidin, MTA-Angelus and Dycal showed either mild or moderate inflammation at 2 weeks with significant differences between subgroups (P < .05). At 4 and 8 weeks, there were no significant differences between subgroups (P > .05). Absence of complete or partial calcified bridge with no odontoblastic layer was reported in all subgroups at 2 weeks while at 4 weeks, the majority of samples in Hesperidin and MTA subgroups showed amorphous calcified deposit. At 8 weeks, there was no significant difference (P > .05) between subgroups except that 78.5% and 92.9% of Hesperidin and MTA-Angelus samples, respectively, showed moderate dentine bridge. Also, 78.5% of Hesperidin and Dycal samples revealed moderately thick dentine bridge while 78.7% of MTA-Angelus showed a thin dentine bridge with a significant difference between them (P < .05). In conclusion, Hesperidin is a promising pulp capping material inducing mild inflammation and good dentine bridge formation.
Keyphrases
  • gestational age
  • inflammatory response
  • oxidative stress
  • clinical trial
  • phase iii
  • machine learning
  • electronic health record
  • big data
  • combination therapy
  • study protocol
  • solid state